A novel immunogenomic classification for prognosis in non-small cell lung cancer

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Journal of Cancer Research and Clinical Oncology

• Publication date

  2023-06-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00432-023-04887-9PMID 37329462PMCID PMC11797223
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The foundations of immune checkpoint blockade and the ipilimumab approval decennial

  2021cited by this paper
• Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non–Small Cell Lung Cancer

  2021cited by this paper
• Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer

  2021cited by this paper
• The Pyroptosis-Related Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Gastric Cancer

  2021cited by this paper
• Detection of Immune Checkpoint Receptors – A Current Challenge in Clinical Flow Cytometry

  2021cited by this paper
• Toward personalized treatment approaches for non-small-cell lung cancer

  2021cited by this paper
• TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer

  2021cited by this paper
• IL-6 stimulates lncRNA ZEB2-AS1 to aggravate the progression of non-small cell lung cancer through activating STAT1.

  2020cited by this paper
• STAT1-induced upregulation of lncRNA KTN1-AS1 predicts poor prognosis and facilitates non-small cell lung cancer progression via miR-23b/DEPDC1 axis

  2020cited by this paper
• Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

  2019cited by this paper
• IRF1 Negatively Regulates Oncogenic KPNA2 Expression Under Growth Stimulation and Hypoxia in Lung Cancer Cells

  2019cited by this paper
• The Human Transcription Factors.

  2018cited by this paper
• The Human Transcription Factors.

  2018cited by this paper
• The Lineage‐Defining Transcription Factors SOX2 and NKX2–1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment

  2018cited by this paper
• Urinary levels of prostaglandin E2 are positively correlated with intratumoral infiltration of Foxp3+ regulatory T cells in non-small cell lung cancer.

  2017cited by this paper
• Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma

  2017cited by this paper
• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

  2017cited by this paper
• Present Yourself! By MHC Class I and MHC Class II Molecules.

  2016cited by this paper
• Widespread parainflammation in human cancer

  2016cited by this paper
• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

  2016cited by this paper
• Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.

  2015cited by this paper
• WHO classification of tumours of the lung, pleura, thymus and heart

  2015cited by this paper
• limma powers differential expression analyses for RNA-sequencing and microarray studies

  2015cited by this paper
• Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer

  2015cited by this paper
• A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism.

  2013cited by this paper
• The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-small Cell Lung Cancer

  2011cited by this paper
• Reorganizing the protein space at the Universal Protein Resource (UniProt)

  2011cited by this paper
• Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients.

  2010cited by this paper
• Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer

  2009cited by this paper
• A census of human transcription factors: function, expression and evolution

  2009cited by this paper
• Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

  2008cited by this paper
• Immune escape as a fundamental trait of cancer: focus on IDO

  2008cited by this paper
• Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer

  2008cited by this paper
• Cancer despite immunosurveillance: immunoselection and immunosubversion

  2006cited by this paper
• Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study

  2005cited by this paper
• The Cellular Pathway of CD1e in Immature and Maturing Dendritic Cells

  2005cited by this paper
• CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non‐small cell lung cancers

  2003cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• The accumulated evidence on lung cancer and environmental tobacco smoke

  1997cited by this paper

• An electrochemical method based on CRISPR-Cas12a and enzymatic reaction for the highly sensitive detection of tumor marker MUC1 mucin.

  2024cites this paper